Loading clinical trials...
Loading clinical trials...
Assessing the clinical efficacy of weizmannia coagulans BC99 in alleviating allergic rhinitis symptoms, improving gut microbiota, and reducing adverse reactions in patients.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Wecare Probiotics Co., Ltd.
NCT06547372 · Atopic Dermatitis, Atopic, and more
NCT07419230 · Allergic Rhinitis
NCT07453615 · Anxiety, Fear Anxiety, and more
NCT06732414 · Allergy, Sinus Disorders, Atopic Diseases, Asthma, Allergic Rhinitis, Atopic Dermatitis, EoE, Drug a
NCT05494346 · Acute Rhinitis, Nasal Obstruction, and more
School of Food and Bioengineering, Henan University of Science and Technology
Luoyang, Henan
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions